Scott Thomas Smith Purchases 100 Shares of Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S (NASDAQ:ASND) CFO Scott Thomas Smith bought 100 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were acquired at an average price of $219.00 per share, with a total value of $21,900.00. Following the purchase, the chief financial officer owned 4,367 shares in the company, valued at $956,373. This trade represents a 2.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $216.79 on Thursday. The business has a 50 day moving average price of $233.30 and a 200 day moving average price of $223.59. Ascendis Pharma A/S has a twelve month low of $160.86 and a twelve month high of $250.74. The company has a market cap of $13.52 billion, a price-to-earnings ratio of 25.00 and a beta of 0.39. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.11. The business had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. Research analysts predict that Ascendis Pharma A/S will post 11.72 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently modified their holdings of the stock. Parallel Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 94.9% during the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after buying an additional 148 shares during the period. Perceptive Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares during the last quarter. Eagle Health Investments LP acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth about $19,819,000. Finally, Empowered Funds LLC increased its position in shares of Ascendis Pharma A/S by 39.3% during the 1st quarter. Empowered Funds LLC now owns 51,135 shares of the biotechnology company’s stock worth $11,696,000 after purchasing an additional 14,438 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Morgan Stanley restated an “overweight” rating and set a $256.00 price target on shares of Ascendis Pharma A/S in a research note on Thursday, February 12th. Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Royal Bank Of Canada boosted their price target on Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Oppenheimer boosted their price target on Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Finally, Barclays boosted their price target on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Buy” and an average target price of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.